Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Neurology · Autosomal Dominant Hereditary Spastic Paraplegia

Prognosis and Living Well with AD-HSP

At a Glance

AD-HSP is a slowly progressive condition that unfolds over decades, with symptom severity varying widely even among family members. Managing the disease focuses on maintaining quality of life by tracking mobility changes and addressing non-motor symptoms like chronic pain and fatigue.

Living with Complex Autosomal Dominant Hereditary Spastic Paraplegia (AD-HSP) is a journey of adaptation. Because the condition progresses slowly—unfolding over decades rather than months—the focus shifts from finding a “cure” to maintaining the best possible quality of life at every stage [1][2].

Understanding Your Outlook

One of the most challenging parts of AD-HSP is its variability [3]. You may notice that even members of the same family with the identical gene mutation can have very different experiences [4][5].

  • Variable Progression: Some people may maintain the ability to walk independently for their entire lives, while others may eventually require a mobility aid like a walker or a wheelchair for longer distances [6][7].
  • Genetic Modifiers: Scientists have discovered that other “modifier” genes, such as DPY30 or SARS2, can act like a volume knob—turning the age of onset up or down regardless of the primary mutation [8][9].
  • Complex vs. Pure: In complex forms, the prognosis is also shaped by non-motor symptoms like cognitive changes (especially executive function) or peripheral neuropathy, which require their own specific management [10][11].

How Doctors Track Your Progress

To provide the best care, your medical team uses objective tools to see how you are doing over time:

  • SPRS (Spastic Paraplegia Rating Scale): This is the “gold standard” tool used by neurologists. It is a 13-item scale that tracks leg stiffness, weakness, and your ability to walk [12][7]. Scoring is used not just to monitor you, but also to help researchers design future clinical trials [12].
  • Gait Analysis: Measuring how fast you walk (gait speed) is a powerful way to track physical disability and predict your risk of falling [13].
  • Biomarkers (NfL): You may hear about a blood test called Neurofilament Light Chain (NfL). While it is a helpful marker of nerve injury, current research suggests it cannot yet be used as a reliable “speedometer” to predict how fast your disease will move in the future [14][15].

Prioritizing Quality of Life

Maintaining well-being with AD-HSP involves looking beyond just your legs. Research shows that non-motor factors often have the biggest impact on how you feel day-to-day [2][16].

  • Social Participation: Staying connected to your community and finding ways to continue the activities you love—perhaps with adaptations—is vital for preventing isolation [2].
  • Addressing the “Invisible” Symptoms: Managing bladder urgency, chronic pain, and fatigue is just as important as managing your walking [16][2].
  • Mental Health: Living with a rare, progressive condition involves a significant amount of uncertainty. Many patients find that working with a therapist or joining a support group helps them manage the anxiety of “what comes next” [2].

While the path of AD-HSP is a long one, proactive monitoring and a focus on holistic well-being can help you navigate the changes with resilience and confidence [17][16].

Common questions in this guide

How fast does AD-HSP progress?
AD-HSP typically progresses slowly over decades rather than months. The rate of progression varies widely, even among family members with the exact same genetic mutation, and can be influenced by other modifying genes.
Will I eventually need a wheelchair if I have AD-HSP?
Mobility outcomes vary significantly from person to person. While some individuals maintain independent walking throughout their lives, others may eventually require mobility aids like a walker or wheelchair for longer distances.
What is the Spastic Paraplegia Rating Scale (SPRS)?
The SPRS is a standardized 13-item tool used by neurologists to track disease progression. It measures your leg stiffness, weakness, and walking ability over time to help guide your treatment plan.
What are the non-motor symptoms of complex AD-HSP?
Complex forms of AD-HSP can involve symptoms beyond walking difficulties. These frequently include cognitive changes, peripheral nerve damage, bladder urgency, chronic pain, and fatigue.
What is the NfL blood test used for in AD-HSP?
The Neurofilament Light Chain (NfL) test is a marker of nerve injury. While helpful for researchers, current evidence suggests it is not yet a reliable tool for predicting how fast your specific disease will progress.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current score on the Spastic Paraplegia Rating Scale (SPRS), and how has it changed since our last visit?
  2. 2.Are there specific 'complex' symptoms, like changes in my executive function or peripheral nerves, that we should be screening for more frequently?
  3. 3.Given the variability in my family, do we know if I have any known genetic modifiers (like DPY30 or SARS2) that might affect my progression?
  4. 4.What are the specific milestones or changes in my mobility that should trigger a conversation about new assistive devices or home modifications?
  5. 5.Can you refer me to a mental health professional or support group that specializes in chronic, rare neurodegenerative conditions?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Anaesthesia and orphan disease: Management of a case of Strumpell-Lorrain disease and review of the literature.

    Ponsonnard S, Damon A, Gueye EM

    European journal of anaesthesiology 2017; (34(8)):562-563 doi:10.1097/EJA.0000000000000615.

    PMID: 28682816
  2. 2

    Health-Related Quality of Life in Rare Forms of Childhood-Onset Hereditary Spastic Paraplegia.

    Schmidt HJD, Battaglia N, Rong J, et al.

    Annals of clinical and translational neurology 2026; (13(1)):193-199 doi:10.1002/acn3.70244.

    PMID: 41199121
  3. 3

    Cognitive dysfunction in hereditary spastic paraplegias and other motor neuron disorders.

    Faber I, Branco LMT, França Júnior MC

    Dementia & neuropsychologia 2016; (10(4)):276-279 doi:10.1590/s1980-5764-2016dn1004004.

    PMID: 29213469
  4. 4

    Locus and allelic heterogeneity in five families with hereditary spastic paraplegia.

    Hebbar M, Shukla A, Nampoothiri S, et al.

    Journal of human genetics 2019; (64(1)):17-21 doi:10.1038/s10038-018-0523-y.

    PMID: 30337681
  5. 5

    A novel homozygous mutation of the TFG gene in a patient with early onset spastic paraplegia and later onset sensorimotor polyneuropathy.

    Miyabayashi T, Ochiai T, Suzuki N, et al.

    Journal of human genetics 2019; (64(2)):171-176 doi:10.1038/s10038-018-0538-4.

    PMID: 30467354
  6. 6

    Hereditary spastic paraplegia caused by compound heterozygous mutations outside the motor domain of the KIF1A gene.

    Krenn M, Zulehner G, Hotzy C, et al.

    European journal of neurology 2017; (24(5)):741-747 doi:10.1111/ene.13279.

    PMID: 28332297
  7. 7

    Toward the Definition of Patient-Reported Outcome Measurements in Hereditary Spastic Paraplegia.

    Amprosi M, Indelicato E, Eigentler A, et al.

    Neurology. Genetics 2023; (9(1)):e200052 doi:10.1212/NXG.0000000000200052.

    PMID: 36636734
  8. 8

    Mechanistic basis of an epistatic interaction reducing age at onset in hereditary spastic paraplegia.

    Newton T, Allison R, Edgar JR, et al.

    Brain : a journal of neurology 2018; (141(5)):1286-1299 doi:10.1093/brain/awy034.

    PMID: 29481671
  9. 9

    The mitochondrial seryl-tRNA synthetase SARS2 modifies onset in spastic paraplegia type 4.

    Parodi L, Barbier M, Jacoupy M, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2022; (24(11)):2308-2317 doi:10.1016/j.gim.2022.07.023.

    PMID: 36056923
  10. 10

    Cognitive impairment in hereditary spastic paraparesis: An overlooked aspect of a motor disorder.

    Falcone GMI, Bonanno L, Graceffa AMS, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(2)):199 doi:10.1007/s10072-026-08830-x.

    PMID: 41586951
  11. 11

    Identification of a novel mutation in ATP13A2 associated with a complicated form of hereditary spastic paraplegia.

    Odake Y, Koh K, Takiyama Y, et al.

    Neurology. Genetics 2020; (6(5)):e514 doi:10.1212/NXG.0000000000000514.

    PMID: 33134512
  12. 12

    Natural history in hereditary spastic paraplegias: real-world data from an Austrian cohort.

    Amprosi M, Indelicato E, Eigentler A, et al.

    Journal of neurology 2026; (273(2)):97.

    PMID: 41586880
  13. 13

    Mobile digital gait analysis objectively measures progression in hereditary spastic paraplegia.

    Loris E, Ollenschläger M, Greinwalder T, et al.

    Annals of clinical and translational neurology 2023; (10(3)):447-452 doi:10.1002/acn3.51725.

    PMID: 36622133
  14. 14

    Longitudinal Dynamics of Plasma Neurofilament Light Chain in Hereditary Spastic Paraplegia Type 11 (HSP-SPG11) and Type 15 (HSP-ZFYVE26).

    Agianda HAP, Alecu JE, Tam A, et al.

    Movement disorders : official journal of the Movement Disorder Society 2026; (41(3)):785-791 doi:10.1002/mds.70142.

    PMID: 41365832
  15. 15

    Serum NfL, but not GFAP, differentiates primary lateral sclerosis from adrenomyeloneuropathy and hereditary spastic paraplegia type 4.

    Kessler C, Wilke C, Hengel H, et al.

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2026; (27(1-2)):110-117 doi:10.1080/21678421.2025.2557936.

    PMID: 40961460
  16. 16

    Stumbling, struggling, and shame due to spasticity: a qualitative study of adult persons with hereditary spastic paraplegia.

    Kerstens HCJW, Satink T, Nijkrake MJ, et al.

    Disability and rehabilitation 2020; (42(26)):3744-3751 doi:10.1080/09638288.2019.1610084.

    PMID: 31079503
  17. 17

    Pathophysiology, diagnostic work-up and management of balance impairments and falls in patients with hereditary spastic paraplegia.

    Nonnekes J, van Lith B, van de Warrenburg BP, et al.

    Journal of rehabilitation medicine 2017; (49(5)):369-377 doi:10.2340/16501977-2227.

    PMID: 28471471

This page provides educational information on the prognosis and daily management of AD-HSP. Always consult your neurologist for personalized medical advice and progression monitoring.

Get notified when new evidence is published on Autosomal dominant complex spastic paraplegia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.